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Summary
A possible way to avoid dose-limiting side effects of
platinum anticancer drugs is to employ light to cause
photochemical changes in nontoxic platinum pro-
drugs that release active antitumor agents. This strat-
egy could be used in the treatment of localized cancers
accessible to irradiation (e.g., bladder, lung, esopha-
gus, and skin). We report here that nontoxic photola-
bile diam(m)ino platinum(IV) diazido complexes inhibit
the growth of human bladder cancer cells upon irradi-
ation with light, and are non-crossresistant to cis-
platin. Their rate of photolysis closely parallels that of
DNA platination, indicating that the photolysis prod-
ucts interact directly, and rapidly, with DNA. Photoacti-
vation results in a dramatic shrinking of the cancer
cells, loss of adhesion, packing of nuclear material,
and eventual disintegration of their nuclei, indicating
a different mechanism of action from cisplatin.
Introduction
The platinum diammine complexes cisplatin and carbo-
platin are highly effective anticancer drugs, but their use
is limited by dose-limiting side effects, by their restricted
spectrum of anticancer activity, and by the development
of resistance after repeated use in treatment [1]. As an
approach to the avoidance of toxic side effects, we are
exploring the use of light in causing photochemical
changes in nontoxic platinum prodrugs that then release
active antitumor agents [2–4].
In general, the d-shells of transition metal ions are
a rich source of electronic transitions in the visible re-
gion of the spectrum. Particularly intense transitions
can arise from ligand-to-metal or metal-to-ligand charge
transfer (LMCT and MLCT). Examples of MLCT include
RuII complexes, which are useful in studies of electron
transfer pathways in proteins [5] and DNA [6]. Impor-
tantly, photoactivated excited-state metal complexes
often possess enhanced chemical reactivity compared
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ed.ac.uk (P.J.S.)to the ground state. We have chosen octahedral 5d6
PtIV complexes, which possess LMCT bands, for photo-
activation studies because they are kinetically inert un-
der biological conditions and can undergo two-electron
reduction to form potentially reactive square-planar PtII
complexes [7]. The orally active PtIV drug JM216, for ex-
ample (Figure 1A), undergoes chemical reduction in vivo
to form active PtII analogs [8]. PtIV complexes containing
iodo ligands (e.g., trans, cis-[Pt(en)(OAc)2I2] [en = ethyl-
enediamine]) possess intense LMCT bands and are
photoactive, but biological thiols, particularly glutathi-
one (GSH), readily attack the coordinated iodo ligand
[9]. This leads to a premature reduction of PtIV to PtII,
and makes these iodo complexes unsuitable for in vivo
use.
Recently, we synthesized the photolabile diazido PtIV
complexes cis, trans, cis-[Pt(N3)2(OH)2X2] 4 (X = NH3)
and 5 (X2 = en), potentially prodrugs of the Pt
II anticancer
complex 1 (cisplatin) and its ethylenediamine analog 2,
respectively (Figure 1A) [10]. These PtIV complexes pos-
sess intense azide-to-PtIV charge-transfer bands, and
the presence of axial hydroxo ligands decreases the re-
duction potential [7], and therefore increases stabiliza-
tion of PtIV relative to PtII (in the dark). Indeed, we found
[10] that the presence of 5 mM GSH (within the concen-
tration range found in cancer cells [11]) had little effect
on the stability of complex 4. It seemed likely, therefore,
that these complexes might reach the nucleus of cancer
cells intact and exhibit phototoxicity.
Here we have studied the effects of complexes 4 and 5
on the growth and morphology of human bladder cancer
cells, both in the dark and in the light, and the photolysis
of the complexes in the absence and presence of a dinu-
cleotide (d(GpG)) and DNA using irradiation conditions
similar to those for the cell work. Intriguingly, G-G ad-
ducts were formed much more rapidly via photoactiva-
tion of the diazide complexes than they were with cis-
platin, and no crossresistance to cisplatin in cancer cells
was observed.
Results and Discussion
Cytotoxicity Studies
First, we investigated the effect of the photoactivation of
complexes 4 and 5 on the growth of 5637 human bladder
cancer cells. Control experiments showed no phototox-
icity in these cells on irradiation at l = 366 nm, and azide
itself was relatively nontoxic (50% growth inhibitory
concentration (IC50) = 3.1 mM in the dark, 2.8 mM with
light). When the cancer cells were treated with com-
plexes 4 and 5 for 6 hr at 37ºC in the dark, the complexes
exhibited very low inhibition of growth (Figure 1B). When
they were irradiated with light (l = 366 nm; I = 5.23 1028
einsteins min21) during a 6 hr treatment, a selective inhi-
bition of cell growth was observed, and the IC50 values
decreased significantly from >300 mM to 49 and 63 mM
for complexes 4 and 5, respectively (Figure 1C). In con-
trast, the growth-inhibitory activities of both cisplatin (1)
and the ethylenediamine complex 2 were unaffected
by light. Cisplatin and 2 are more potent than their
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not an unexpected finding, because the antitumor drugs
carboplatin and oxoplatin, prodrugs of cisplatin that are
chemically less reactive than the parent drug, are ap-
proximately 10- to 15-fold less active in the 5637 cell
line compared to cisplatin.
Importantly, when irradiated, the platinum diazide
complexes were equally toxic to 5637 and cisplatin-
resistant 5637 cells (5637-CDDP). The 5637-CDDP cells
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Figure 1. Effect of Light on the Activity of Platinum Diazido Com-
plexes 4 and 5 toward Human Bladder Cancer Cells
(A) Structures of complexes 4 and 5, and of cisplatin 1, its chelated
ethylenediamine (en) analog 2, and the Pt(IV) complex 3 (JM216),
which has been in clinical trials and is activated by chemical reduc-
tion.
(B) 5637 Human urinary bladder cancer cells (German Collection of
Microorganisms and Cell Culture, No. ACC 35) were seeded into
96-well microtiter plates and grown for 24 hr before treatment. Cells
were exposed to 5 concentrations of 4 (triangles) or 5 (squares), re-
spectively, for 6 hr at 37ºC, either in the dark (closed symbols)
or with concurrent irradiation (open symbols). After the 6 hr drug
exposure, the culture medium was replaced with fresh medium
without HEPES, and the cells were then allowed to grow for an ad-
ditional 90 hr. Data points represent the averages of four indepen-
dent experiments, and error bars represent standard deviations.
With the exception of the lowest concentration, the differences be-
tween the paired results from light and dark experiments are statis-
tically significant (p < 0.01, two-sided, paired Student’s t test). Error
bars represent 61 SD.
(C) IC50 values for the inhibition of cell growth by complexes 4, 5,
cisplatin, and [Pt(en)Cl2] in the 5637 cell line and cisplatin-resistant
5637 cell line (5637-CDDP), with and without a concurrent irradia-
tion with light for 6 hr at 37ºC. A two-sided, paired Student’s t
test was used to establish statistical significance.exhibited a resistance factor (RF = IC50[5637CDDP]/
IC50[5637]), of approximately 5 (both in the presence
and absence of light), whereas RF was approximately 1
for the diazide complexes 4 and 5 in the presence of light
(Figure 1C). This suggests that the mechanisms of cyto-
toxicity are different for cisplatin and the cytotoxic prod-
ucts of photolysis.
Fluorescence Microscopy
Changes in the morphologies of 5637 cells after expo-
sure to either cisplatin, complexes 4 (cis, trans, cis-
[Pt(N3)2(OH)2(NH3)2]) or 5 (cis, trans-[Pt(en)(N3)2(OH)2]),
both in the dark and in the light, were investigated by
fluorescence microscopy. Cells treated for 6 hr with ei-
ther 1.25 or 2.5 mM cisplatin showed no changes in their
morphologies 17 hr following treatment (data not shown).
At 90 hr after exposure to 2.5mM cisplatin (approximately
the IC30 concentration), the cells had grown larger than
the controls, and possessed a multitude of white va-
cuoles (Figure 2A). The fluorescing nuclei also appeared
larger and were more diffuse than in the control cells, and
fluorescence could be seen in the cytoplasm. Neverthe-
less, the cells maintained contact with each other. Inter-
estingly, the classic hallmarks of apoptosis (i.e., shrink-
age and condensation of the cell, packing of the nuclear
material, budding and cellular fragmentation, and nu-
clear breakup [karyolysis]) were not observed [12].
The effects of 4 on cellular and nuclear morphologies
were documented 17 and 90 hr after a 6 hr treatment with
and without irradiation with light (l = 366 nm). Represen-
tative results for compound 4 are shown in Figure 2. In
contrast to cisplatin, complex 4 had already caused
rounding (‘‘ballooning’’) of the cells by the end of the
6 hr irradiation period (Figure 2B). At 17 hr, the changes
were characterized by cellular shrinkage and loss of
contact with neighboring cells, as well as the plastic
bottoms of the culture vessel (Figure 2C). Nuclear pack-
ing was dramatic in the fluorescence images, especially
for cells treated with 100 mM complex. The cytoplasm
also showed some fluorescence. At 90 hr, some of the
cells had survived in the presence of the complex at
doses of 25 and 50 mM, but they appeared larger than
the control cells, with enlarged nuclei (Figure 2D). With
100 mM of the complex present (approximately the IC30
concentration), however, the only cells that remained
were shrunken, and most lacked a nucleus. Those nuclei
still remaining were small and weakly stained, suggest-
ing nuclear breakup. However, budding and cellular
fragmentation were not observed, as would be expected
with apoptosis [12].
These dramatic changes in the morphology of the cells
were observed only when treatment with complex 4 was
accompanied by irradiation. Without light, no changes in
the cells were seen up to a concentration of 100 mM of 4
(Figure 2E). At 500 mM, the cells appeared to take on an
appearance similar to that of cells treated with cisplatin.
Comparable effects on the appearance of 5637 cells
were found with complex 5 (see Figure S1 in the Supple-
mental Data available with this article online). These re-
sults indicate that photoactivatable complexes 4 and 5
cause a very different cytotoxicity compared with cis-
platin. Further work will be required to elucidate the
exact mechanism of cell death caused by the light-
activated PtIV complexes; however, these initial results
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nism of cell death.
Cell Uptake
We then studied the effect of light on the time-depen-
dent uptake of complexes 4 and 5 by 5637 bladder can-
cer cells by atomic absorption spectroscopy (AAS). It is
evident that light has no significant effect on Pt uptake
up to 8 hr (Figure S2). Over the same time period, cis-
platin reached approximately 5-fold higher concentra-
Figure 2. Phase-Contrast and Fluorescence Microscopy Studies at
4003 Magnification of the Effect of Platinum Complexes and of
Light on the Morphology of 5637 Cells and Their DNA Distribution
Cells were seeded into NUNC SonicSeal slide wells and allowed to
grow for 24 hr before treatment.
(A) Effect of light but no addition of platinum, and 90 hr after a 6 hr
treatment with cisplatin (without irradiation).
(B) Immediate effects of 100 mM 4 on 5637 cells after a 6 hr treat-
ment without (left image), and with (right image) irradiation with
light. Scale bar = 50 mm.
(C) At 17 hr after a 6 hr treatment with complex 4 with a 6 hr con-
current irradiation with light (l = 366 nm).
(D) At 90 hr after a 6 hr treatment with complex 4 with 6 hr concur-
rent irradiation with light.
(E) At 90 hr after a 6 hr treatment without a 6 hr concurrent irradia-
tion with light.tions of intracellular platinum, explaining some of the re-
duced activity of 4 compared with 1.
Stability and Photoactivation
Next, the effect of light, of the same wavelength and in-
tensity, on the stability of the complexes alone was in-
vestigated. The complexes were stable in phosphate
buffer pH 7.4 in the dark at 37ºC, Figure 3, but decom-
posed in the presence of light. This was also confirmed
by 2D [1H, 15N] NMR studies of 15N-labeled complexes
(Figure S3), which show the existence of photoisomeri-
zation and photoreduction pathways. 15N NMR peaks
with chemical shifts in the range266 to273 ppm charac-
teristic of 15NH3-Pt
II species were clearly visible after ir-
radiation of an aqueous solution of the diammine com-
plex 4 for 26 min. After 246 min, the major crosspeaks
in the 2D [1H, 15N] HSQC NMR spectrum (Figure S3A)
had 1H, 15N shifts of 4.02, 268.59 ppm (peak b), 3.87,
266.79 ppm (peak c), and 4.03,272.60 ppm (peak d, mi-
nor). The 1J(15N-195Pt) coupling constants associated
with species b and c (286 Hz) suggest that they contain
N ligands trans to Pt-NH3 groups [13]; possible N ligands
include NH3 (which would require isomerization of the
Pt(NH3)2 unit) or a breakdown product of azide. For the
ethylenediamine complex 5, a PtII product (d(1H), d(15N)
5.11, 233.43, Figure S3B) was detected after only 11
min. The 1J(15N-195Pt) value of 377 Hz suggests that
this is likely to be an aqua or hydroxo complex. It is nota-
ble that these products of photolysis are not the major
products when nucleotides are present in irradiated
solutions, suggesting that they or their precursors are
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Figure 3. Effect of Light on the Stability of Platinum Diazido Com-
plexes
(A) Complex 4, and (B) complex 5, in the presence (open symbols)
and absence (closed symbols) of light. Solutions of the complexes
(0.3–1.0 mM) in 50 mM phosphate buffer (pH 7.4) were incubated in
96-well plates (200 ml/well) at 37ºC (water bath) and irradiated at a
distance of 17 cm from a 40 W Lamag UV lamp (l= 366 nm; intensity =
5.2 6 0.1 3 1028 einsteins min21). Error bars represent 61 SD.
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64highly reactive with nucleobases (see below, Figures 4
and S4).
DNA Binding
Since the target for cisplatin and related anticancer
drugs is DNA [14], we investigated the platination of
calf thymus DNA by complexes 4 and 5 in the dark and
with light of the same intensity and wavelength as in
the cell experiments. The photolysis rates (Figure 3)
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Figure 4. Binding of Photoactivated Platinum Diazido Complexes 4
and 5 to DNA
(A) Mixtures of Pt complexes (15 mM) and calf thymus DNA
(0.25 mg/ml) in 10 mM PIPES buffer (pH 6.9) were incubated in
96-well microtiter plates (200 ml/well) at 37ºC for various times in
the dark (:), or in the light (6; 17 cm from a 40 W Lamag UV
lamp, l = 366 nm; intensity = 5.2 6 0.1 3 1028 einsteins min21).
The time-dependent changes in the amounts of Pt bound to DNA
were determined using a flameless atomic absorption spectros-
copy (AAS) method. Note that platination ceases when the light is
switched off at 6 hr. Error bars represent 61 SD.
(B) 2D [1H, 15N] HSQC NMR spectrum of a solution containing 5 cis,
trans-[Pt(15N-en)(N3)2(OH)2] (0.75 mM) and d(GpG) (0.5 mM) after ir-
radiation for 26 min (l = 365 nm). The inset graph shows that forma-
tion of the crosslinked PtII adduct is complete within 30 min. Some
photo-induced isomerization/substitution of the PtIV starting com-
plex is also evident.closely parallel the rates of irreversible DNA platination
by these two complexes (Figure 4A), indicating that the
photolysis products react directly with DNA. The platina-
tion of DNA is directly dependent on light, and almost
ceases when the light is switched off at 6 hr. Two-dimen-
sional [1H, 15N] NMR studies of 15N-labeled complexes
provided further insight into the nature of the photo-
chemical decomposition processes and their reactions
with DNA bases. Irradiation of complex 5 in the presence
of d(GpG) quickly gave rise to new crosspeaks (Figure
4B), assignable to PtIV isomers/substitution products
and to the PtII species [Pt(15N-en)d(GpG)-N7,N7], an in-
trastrand GG crosslink of the type formed by cisplatin
on DNA. The 1H NMR spectra in Figure S4 confirm that
binding occurs to N7 of G. Overall, the photoreaction
can be represented as:
Pt
N
H2
N3
N3
H2
N
OH
OH
Pt
N
H2
G
G
H2
N
+ 3N2
d(GpG)
hν
It is notable that platination of DNA can occur more
rapidly via this photoactivation pathway than by the
usual chemical activation of cisplatin, which is deter-
mined by slow, rate-limiting hydrolysis steps [15, 16].
Significance
Stable cis-diam(m)ine trans-dihydroxo platinum(IV)
diazido complexes bind to DNA rapidly upon acti-
vation by visible light, and can give rise to d(GpG)
crosslinks of the type produced on DNA by the anti-
cancer drug cisplatin. Intriguingly, the GG adducts
are formed much more rapidly via photoactivation of
diazide complexes than they are with cisplatin. The
photoactivatable PtIV diazido complexes studied here
platinate DNA by a different pathway to cisplatin,
which involves the step-wise hydrolysis of the bound
chloride ligands. The products from photolysis of 4
and 5 appear to react directly with DNA. Photoactiva-
tion may give rise to reactive products that do not
have counterparts for PtII drugs. These PtIV diazido
complexes are nontoxic to 5637 human bladder cancer
cells in the dark, but are toxic to the cells upon irradi-
ation. Photoactivation causes dramatic effects on the
morphology of bladder cancer cells, including disinte-
gration of their nuclei. The mechanism by which they
kill cancer cells, therefore, appears to be different
from that of cisplatin. Indeed, we found that these plat-
inum diazido complexes were equally cytotoxic to
5637 cells and cisplatin-resistant 5637 cells. This
new class of photoactivatable platinum complexes
could, therefore, be useful in the treatment of cancers
that are accessible to light, including bladder, lung,
esophagus, and skin cancers. Since activation can
be localized to the area of irradiation, this procedure
has potential for avoiding the side effects that often ac-
company the use of cisplatin. Existing photodynamic
agents rely on the conversion of ground state triplet
oxygen to toxic singlet-state oxygen [17]. The activity
of platinum diazide complexes does not rely on the
presence of oxygen, which is a potential advantage,
as some tumors are oxygen deficient.
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Materials
The human bladder cancer cell line 5637 (ACC 35) [18] was obtained
from the German Collection of Microorganisms and Cell Culture
(Brauschweig, Germany). The cisplatin-resistant cell line, 5637-
CDDP, was raised from the 5637 line in our laboratories, as previ-
ously described [19]. Cell culture media, serum, antibiotics, tryp-
sin/EDTA, DAPI, and spectral-grade DMF were from Sigma-Aldrich
(Taufkirchen, Germany). Porcine pancreatin was from Fluka (Tauf-
kirchen, Germany), and HEPES was from Merck (Darmstadt, Ger-
many). All plastic culture supplies were from Starsted (Nu¨mbrecht,
Germany). Cisplatin was obtained from ChemPur (Karlsruhe, Ger-
many). Complexes 4, 5, and [Pt(en)Cl2] were synthesized in our lab-
oratories following published procedures [10].
NMR
1D [1H], 2D [1H,15N] HSQC NMR spectra were recorded on a Bruker
DMX 500 NMR spectrometer (1H: 500.13 MHz; 15N: 50.7 MHz; Bruker
UK Ltd., Coventry, UK) in 90% H2O/10% D2O, using dioxane (3.764
ppm) as the internal d(1H) standard. All d(15N) values were referenced
externally to 15NH4
+ at d = 0 ppm. The pH value of all samples was
adjusted to 5 with HClO4 before recording spectra so as to ensure
slow exchange (on the NMR time scale) of NH protons of the PtIV
species present. Spectra were acquired at 25ºC, and processed us-
ing Xwinnmr (version 2.0, Bruker UK Ltd.) software. The light source
was a 365 nm UV lamp (23 15 W tubes, model VL-215L; Merck Euro-
lab, Poole, UK).
Cytotoxicity Studies
The cell lines were maintained in RPMI medium supplemented with
10% fetal calf serum (FCS) and antibiotics (benzylpenicillin and
streptomycin). Cells were kept at 37ºC in an atmosphere of 5%
CO2 air. Under these conditions, the 5637 line achieved a maximum
doubling time of 26 hr.
The 5637 and 5637-CDDP cells were seeded into 96-well micro-
titer plates in 100 ml medium at a density of 1000 cells/well. The
plates were returned to the incubator for 24 hr. The next day, com-
plexes 4 and 5 were dissolved directly in culture medium (supple-
mented with 10 g/l HEPES) to achieve a stock solution of 400 mM.
Medium was then sterilized by filtration through a 0.22 mm Millex
GV filter unit (Millipore, Bedford, MA). The stock solution was serially
diluted 2-fold. The cells in the microtiter plates were treated with
100 ml of either stock solution or the serial dilutions, respectively.
The 5637 cells were exposed to final concentrations of 125, 100,
75, 50, and 25 mM of complexes 4 or 5 with light and 500, 400, 300,
200, and 100 mM without light, while the 5637-CDDP cells were ex-
posed with and without light to 200, 100, 50, 25, and 12.5 mM of
the PtIV complexes. One plate was returned to the incubator (dark
control), while the second was placed in the irradiation apparatus.
The apparatus consisted of a black aluminum block held in a water
bath at 37ºC and placed 17 cm below a Lamag 40 W UV-lamp (l =
366 nm). Studies with a ferrioxalate actinometer [20] estimated the
intensity of UV366-light to be 5.223 10
28 einsteins/min (standard de-
viation, 6 0.12 3 1028 einsteins/min) in the wells of the microtiter
plates with this apparatus. The plate was irradiated for 6 hr. The cul-
ture medium was then removed by aspiration from both the irradi-
ated plate and dark control and replaced with 200 ml fresh medium
before being returned to the incubator for 90 hr. The medium was
discarded, and the cells were fixed with a 1% glutaraldehyde solu-
tion. Staining of the cells with crystal violet, measurement of cell-
bound dye (l = 570 nm), and the calculation of the IC50 values
have been described in detail elsewhere [21].
Fluorescence Microscopy
For the phase-contrast and fluorescence microscopy studies on the
effects of platinum complexes and light on the morphology of 5637
cells and their DNA distribution, cells were first seeded into NUNC
SonicSeal slide wells and allowed to grow for 24 hr before treatment.
Cells were treated with specified concentrations of complexes 4 and
5 in a manner analogous to that described above. A 6 hr treatment
with and without concurrent irradiation with light (l = 366 nm) at
37ºC was performed with the same apparatus as that used for irra-
diation in the cytotoxicity experiments. Treatment was ended by re-placing the medium with fresh medium. The plates were then re-
turned to the incubator for either 17 or 90 hr. After these time
periods, the medium was removed, and the cells were washed
with phosphate buffer, fixed with a 3:1 mixture of methanol:acetic
acid for 10 min, and then stained with 1 mg/ml DAPI in a 1:1 solution
of methanol:PBS for 15 min. Inverse microscopy was carried out on
an Axiovert 200 (Carl Zeiss, Go¨ttingen, Germany) at a magnification
of 4003; cells were irradiated with light at l ex = 365 nm (BP-filter)
and observed at l em > 397 nm (LP-filter).
Cell Uptake
A single-cell suspension of 5637 cells growing as a monolayer was
prepared by trypsinization, and cells were seeded into 25 cm2 cul-
ture vessels at a density of 100,000–180,000 cells per vessel. Cells
were allowed to grow for 3–5 d, at which time they reached a density
of 1–2 3 106 cells per vessel. On the day of treatment, complexes 4
and 5 were dissolved directly in culture medium (supplemented with
10 g/l HEPES) as described above. A portion of the filtrate was di-
luted with culture medium to give a final Pt concentration of 100
mM. The medium from the cells in culture was replaced with 7.5 ml
of medium containing either 4 or 5, at a concentration of either 100
or 150 mM. In the case of cisplatin, a 10 mM solution in DMF was di-
luted by the culture medium to give a final concentration of 50 mM.
The flasks were either returned to the incubator (dark control) or ir-
radiated at l = 366 nm, as described above.
At time t = 0, and at specified time intervals thereafter, the medium
was aspirated out of the flasks, from both a ‘‘dark’’ and ‘‘light’’ flask.
The cells were washed five times with 1 ml PBS, and then 1 ml of
a trypsin/EDTA solution was added for 1 min at 37ºC. Following re-
moval of the trypsin/EDTA solution, the cells were returned to the in-
cubator for 15 min. A cell suspension was made by continuous rins-
ing of the flask bottom with 3 ml Dulbecco’s buffer containing 5%
FCS by means of a 5 ml pipette. From the resulting cell suspension,
200 ml were removed and added to 10 ml Isoton and the number of
cells counted with a Coulter Counter Z2 instrument (Beckman-Coul-
ter, Fullerton, CA). The remaining cell suspension was added to Ep-
pendorf vials and centrifuged for 5 min at 50003 g. The supernatant
was discarded, and the cell pellet was resuspended in 250 ml Dul-
becco’s buffer and centrifuged again. The resulting cell pellet was
stored at 220ºC until further use.
On the day of the AAS analysis, the cell pellets (approximately 106
cells) were thawed and 150 ml of a 1% pancreatin/phosphate buffer
solution was added. The contents were mixed and the vials incu-
bated at 37ºC for 5 min. Samples were cooled to RT before analysis.
For the flameless AAS analysis, a 989 QZ AA spectrometer
(Unicam, Cambridge, UK) equipped with a GF90 oven and autosam-
pler was used. ELC graphite cuvettes were employed in all measure-
ments. Pt was measured at 265.9 nm with a lamp current of 80% and
a slit opening of 0.2 nm. Deuterium lamp compensation was used as
the method for background correction.
For the creation of the standard curve, 5 standards between 12
and 150 ppb Pt were used: 5 ml of standard Pt solutions (in 5%
HNO3) were diluted into 15 ml 1% pancreatin/phosphate buffer solu-
tion in the graphite cuvettes. In the case of the samples, 15 ml ali-
quots of the cell lysates were added to the cuvettes together with
5 ml of 5% HNO3 solution (see Table 1 for details of the temperature
program employed in the analysis).
Table 1. Temperature Program Employed in the Atomic
Absorption Spectroscopic Analysis of Cell Lysates
Phase T (ºC) Length (s)
Heating
Rate (ºC/s)
Argon Flow
(l/min)
Drying 90 55 0 0.1
Pyrolysis 1400 15 100 0.1
Atomization 2500 3 0 0.0
Burn out 2900 3 0 0.2
Cooling 20 10 0 0.2
The standard curves were linear, with a correlation coefficient of ap-
proximately 0.9979. All standards and samples were measure in trip-
licate; the sample-to-sample relative SD was <5%. The day-to-day
reproducibility was between 9% and 22%.
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Solutions of complexes 4 and 5 were prepared at concentrations be-
tween 0.30 and 1.00 mM in 50 mM phosphate buffer (pH 7.4). Ali-
quots of 50 ml were added to each well of a 96-well microtiter plate,
which was placed in the irradiation apparatus described above and
illuminated with light (l = 366 nm) at 37ºC. Parallel to this study,
a second plate, filled with the same solution of either 4 or 5, was
wrapped in aluminum foil to avoid exposure to light and held at
37ºC in the same water bath. Alternating between the light and
dark solutions, the solutions from one row of 8 wells were removed,
mixed together, and a 20 ml aliquot injected into a Merck-Hitachi
HPLC system, consisting of an L-7100 pump, an L-450 diode array
detector, an L-7360 column oven (30ºC), and a Reodyne injector.
The column used for the separation was a (strongly cationic) Nucle-
osil 100-10 SA 2503 4.0 mm column preceded by a 113 4 mm pre-
column of the same material. The eluent consisted of 1:9 acetonitri-
le:phosphate buffer (20 mM, pH 7.0) mixture, set at a flow rate of
0.7 ml/min. Detection was carried out at l = 257 nm. Under these
conditions, complexes 4 and 5 had retention times of 3.8 and
3.9 min, respectively. Peak areas were used for quantification.
Sampling was done at 1 hr intervals for 6 hr. The area of the peak at
t = 0 was arbitrarily set at 100%; the percent area of the remaining
peaks was set relative to that at t = 0. All experiments were repeated
three times.
DNA Binding
Solutions containing 15 mM of complex 4 or 5, 0.25 mg/ml calf thy-
mus DNA, 10 mM NaClO4 and 10 mM PIPES buffer (pH 6.9) were pi-
petted into two 96-well microtiter plates at 50 ml/well. One plate was
wrapped in aluminum foil and placed in a water bath at 37ºC, while
the second plate was placed in the irradiation apparatus and irradi-
ated with light (l = 366) nm at 37ºC. After defined time periods, the
contents of 4 wells (200 ml) were removed, combined, and added
with mixing to 100 ml ice-cold 0.9 M NaOAc solution. To this solution
was added 900 ml ice-cold ethanol, and the 2 ml Eppendorf vials
were closed and dropped into liquid nitrogen. The Eppendorf vials
were removed from the liquid nitrogen and allowed to warm to
220ºC for 30 min. The vials were then centrifuged at 5400 3 g for
10 min at 29ºC to pellet the precipitated DNA. The DNA pellet was
resuspended in 300 ml 0.3 M NaOAc, precipitated again with 900 ml
ice-cold ethanol, frozen in liquid nitrogen, and thawed to220ºC be-
fore pelleting the precipitated DNA. This procedure was repeated
once more before the DNA was taken up in a solution of 500 ml
0.5% HNO3 and incubated for 2 d at 70ºC to hydrolyze the DNA.
The concentration of DNA bases was measured with a spectro-
photometer at l = 260 nm (e = 8900 M21 cm21). The amount of Pt
was determined using a flameless 989QZ AAS (Unicam) set at l =
265.9 nm using 10 ml of sample. The quantification range was
0.25–2.95 mM Pt. Each sample was measured twice and averaged
(see Table 2 for the temperature-time program of the spectrophoto-
metric analysis).
The R value was calculated as the quotient of platinum bound to
DNA to the amount of DNA nucleotides (R = platinum [mmol]/DNA
nucleotides [mmol]). The ratio of R/Rmax, where Rmax = 0.019 at
0.25 mg/ml DNA, is the fraction of total Pt bound to DNA. All experi-
ments were repeated three times.
Supplemental Data
Figures showing phase-contrast and fluorescence microscopy of
5637 cells, effect of light on cellular uptake of platinum, effect of ir-
radiation on complexes 4 and 5, and NMR studies of GG adduct for-
mation are available at http://www.chembiol.com/cgi/content/full/
13/1/61/DC1/.
Table 2. Temperature Program Employed in the Atomic
Absorption Spectroscopic Analysis of DNA
Temp (ºC) Length (s) Heating Rate (ºC/s) Argon Flow (l/min)
95 30 0 0.1
1400 10 100 0.1
2500 3 0 0.0
2700 3 0 0.2
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